Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.38 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.38 |
| ▸ | ADK | P55263 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1374265 | 1.00 | METTL3 (0.38) | METTL3METTL14ADKPDE4DPDE3A | |
| SCHEMBL1374920 | 0.88 | ADK (0.49) | METTL3ADKPDE4DPDE3ASLC29A1 | |
| SCHEMBL1374921 | 0.88 | ADK (0.49) | METTL3ADKPDE4DPDE3ASLC29A1 | |
| SCHEMBL1736167 | 0.86 | METTL3 (0.40) | METTL3METTL14ADK | |
| SCHEMBL3232370 | 0.84 | ADORA2A (0.39) | METTL3METTL14ADK | |
| SCHEMBL12219557 | 0.84 | ADORA2A (0.42) | METTL3METTL14ADKPDE4DPDE3A | |
| SCHEMBL18661710 | 0.84 | ADORA2A (0.42) | METTL3METTL14ADKPDE4DPDE3A | |
| SCHEMBL12194659 | 0.84 | ADORA2A (0.42) | METTL3METTL14ADKPDE4DPDE3A | |
| SCHEMBL18661709 | 0.84 | ADORA2A (0.42) | METTL3METTL14ADKPDE4DPDE3A | |
| SCHEMBL1375396 | 0.82 | ADORA2A (0.50) | SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120566-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-9249173-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, LLC (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140255339-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20110286962-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. | 2011-11-24 | — | — | US | disclosed |
| US-7951789-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7902202-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| EP-2120566-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX Pharmaceuticals, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090238790-A2 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | IDENIX PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090169504-A1 | Compounds and Pharmaceutical compositions for the treatment of Viral infections | IDENIX PHARMACEUTICALS, INC | 2009-07-02 | — | — | US | disclosed |
| US-20080286230-A1 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
| WO-2008082601-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090169504-A1 | Compounds and Pharmaceutical compositions for the treatment of Viral infections | HAVCR2, PYGL, GYS2 | METTL3 3743/4885METTL14 3862/4885ADK 1032/4885 |
| US-20080286230-A1 | Compounds and pharmaceutical compositions for the treatment of viral infections | HAVCR2, PYGL, GYS2 | METTL3 3743/4885METTL14 3862/4885ADK 1032/4885 |
| US-20090238790-A2 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | HAVCR2, PYGL, GYS2 | METTL3 3743/4885METTL14 3862/4885ADK 1032/4885 |
| US-20140255339-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, PYGL, GYS2 | METTL3 3743/4885METTL14 3862/4885ADK 1032/4885 |
| US-20110286962-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, PYGL, GYS2 | METTL3 3743/4885METTL14 3862/4885ADK 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.